About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials in Tennessee | 898 Studies

Clinical Trials Lung CancerTennessee

Lung Cancer Clinical Trials in Tennessee

Find 898 clinical trials for lung cancer near Tennessee. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 121-140 of 898 trials

CompletedA Dose Finding Study of ZW49 in Patients With HER2-Positive CancersThis is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the…NCT03821233·Duarte, California and 15 others CompletedA Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in…NCT01456325·Chandler, Arizona and 212 others

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedPhase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung CancerThe purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.NCT02580708·St Louis, Missouri and 3 others

TerminatedPhase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibThis is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.NCT02538627·Aurora, Colorado and 4 others

TerminatedEvaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsThe objective of this study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BL-M17D1 in patients with HER2-Expressing or HER2-Mutant Advanced or Metastatic…NCT06714617·Denver, Colorado and 8 others

Active not recruitingErlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)This phase III ALCHEMIST trial studies how well erlotinib hydrochloride compared to observation works in treating patients with stage IB-IIIA non-small cell lung cancer that has…NCT02193282·Birmingham, Alabama and 1406 others

CompletedIspinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung CancerThis study was designed to determine how effective and safe Ispinesib is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a…NCT00085813·Scottsdale, Arizona and 10 others

CompletedSafety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLCThe purpose of this study is to evaluate the objective tumor response rate (based on the RECIST criteria) to SNS-595 as a second-line therapy in patients with advanced NSCLC.NCT00252382·Scottsdale, Arizona and 3 others

TerminatedStudy of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study.NCT04585815·Duarte, California and 54 others

TerminatedStudy of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)1. Part A: Subjects will receive Patritumab or placebo with erlotinib.NCT02134015·Glendale, Arizona and 97 others

Active not recruitingA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsThe purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with…NCT05538130·Birmingham, Alabama and 65 others

RecruitingTesting the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerThis phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and…NCT05624996·Birmingham, Alabama and 476 others

CompletedA Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer ParticipantsThis randomized, active controlled, multicenter phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with crizotinib treatment in…NCT02075840·Northridge, California and 96 others

CompletedRamucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)This phase II Lung-MAP non-Match treatment trial studies how well ramucirumab and pembrolizumab work versus standard of care in treating patients with non-small cell lung cancer…NCT03971474·Mobile, Alabama and 888 others

CompletedSorafenib in Treating Patients With Refractory Non-Small Cell Lung CancerRATIONALE: Preclinical studies indicate that sorafenib is a potent inhibitor of Raf kinase in vitro and in vivo, with significant dose-dependent, anti-tumor activity in four…NCT00064350·Stanford, California and 140 others

TerminatedStudy to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid TumorsThis is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic…NCT04628780·Duarte, California and 12 others

Active not recruitingPhase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyThis is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy.NCT03334617·Duarte, California and 44 others

Active not recruitingA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other…NCT05355701·Fayetteville, Arkansas and 39 others

TerminatedA Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid TumorsThis study is an open-label, multi-center, dose-escalation, dose expansion study in adult subjects with advanced solid tumors.NCT05084859·Tucson, Arizona and 19 others

TerminatedA Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2.NCT00269828·Casa Grande, Arizona and 142 others

PreviousPage 7 of 45Next

Other Conditions in Tennessee

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma